Legend Biotech (NASDAQ:LEGN) is one of the most promising mid-cap healthcare stocks under $50. As of December 19 closing, the ...

Legend Biotech develops CAR-T therapies for hematologic malignancies and solid tumors, aiming to revolutionize cancer therapies. Carvykti, LEGN's commercial product, is a BCMA-directed CAR-T cell ...

Investors are always looking for stocks that are poised to beat at earnings season and Legend Biotech Corporation LEGN may be one such company. The firm has earnings coming up pretty soon, and events ...

Shares of Legend Biotech Corporation Sponsored ADR (LEGN) have been struggling lately and have lost 9.8% over the past week. However, a hammer chart pattern was formed in its last trading session, ...

Fintel reports that on December 8, 2025, UBS maintained coverage of Legend Biotech Corporation - Depositary Receipt (NasdaqGS:LEGN) with a Buy recommendation. Analyst Price Forecast Suggests 166.46% ...

Investors in Legend Biotech Corp (Symbol: LEGN) saw new options begin trading today, for the January 2023 expiration. One of the key data points that goes into the price an option buyer is willing to ...

Good day, ladies and gentlemen. Thank you for standing by. Welcome to Legend Biotech Reports Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only ...

Below is Validea's guru fundamental report for LEGEND BIOTECH CORP (LEGN). Of the 22 guru strategies we follow, LEGN rates highest using our P/B Growth Investor model based on the published strategy ...

LEGN is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of LEGN shares has increased $0.64 since the market last closed. This is a 3.01 ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” first-quarter investor letter. A copy of the letter can be downloaded here. In the ...